Assessment of Metabolic Response to Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Assessment of Metabolic Response to Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma(399 views) Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P, Nardelli A, Speranza A, Klain M, Rotoli B, Pace L
Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata, Rionero in Vulture, Italy
Dipartimento di Biochimica e Biotecnologie Mediche, Università Federico II, 80131 Naples, Italy
Instituto di Biostrutture e Bioimmagini, Consiglio Nazionale Delle Ricerche, Università Federico II, 80131 Naples, Italy
Dipartimento di Scienze Biomorfologiche e Funzionali, Università Federico II, Via Pansini 5, 80131 Naples, Italy
IRCCS, Fondazione Istituto di Diagnostica Nucleare, Naples, Italy
Cheson, B.D., Gregory, S.A., Marcus, R., Emerging treatments for indolent lymphoma (2007) Clin Adv Hematol Oncol, 5 (SUPPL. 8), pp. 1-9
Horning, S.J., Treatment approaches to the low-grade lymphomas (1994) Blood, 83, pp. 881-884
Lemieux, B., Coiffier, B., Radio-immunotherapy in low-grade non-Hodgkin's lymphoma (2005) Best Pract Res Clin Haematol, 18, pp. 81-95
Alcindor, T., Witzig, T.E., Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma (2002) Curr Treat Options Oncol, 3, pp. 275-282
Marcus, R., Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma (2005) Semin Oncol, 32 (1 SUPPL. 1), pp. S36-S43
Jerusalem, G., Beguin, Y., Fassotte, M.F., Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease (2001) Haematologica, 86, pp. 266-273
Castellucci, P., Nanni, C., Farsad, M., Potential pitfalls of 18F FDG PET in a large series of patients treated for malignant lymphoma: Prevalence and scan interpretation (2005) Nucl Med Commun, 26, pp. 689-694
Cheson, B.D., Horning, S.J., Coiffier, B., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group (1999) J Clin Oncol, 17, pp. 1244-1253
Juweid, M.E., Stroobants, S., Hoekstra, O.S., Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma (2007) J Clin Oncol, 25, pp. 571-578
Cheson, B.D., Pfistner, B., Juweid, M.E., The International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25, pp. 579-586
Young, H., Baum, R., Cremerius, U., Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations - European Organization for Research and Treatment of Cancer (EORTC) PET Study Group (1999) Eur J Cancer, 35, pp. 1773-1782
Spaepen, K., Stroobants, S., Dupont, P., Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F] FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: Is [18F]FDGPET a valid alternative to conventional diagnosis methods? (2001) J Clin Oncol, 19, pp. 414-419
Kostakoglu, L., Coleman, M., Leonard, J.P., PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease (2002) J Nucl Med, 43, pp. 1018-1027
Haioun, C., Itti, E., Rahmouni, A., 18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome (2005) Blood, 106, pp. 1376-1381
Torizuka, T., Zasadny, K., Kison, P., Rommelfanger, S.G., Kaminski, M.S., Wahl, R.L., Metabolic response of non-Hodgkin's lymphoma to 131Ianti-B1 radioimmunotherapy: Evaluation with FDG-PET (2000) J Nucl Med, 41, pp. 999-1005
Bodet-Milin, C., Kraeber-Bodéré, F., Dupas, B., Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography (2008) Haematologica, 93, pp. 390-397
Elis, A., Blickstein, D., Klein, O., Eliav-Ronen, R., Manor, Y., Lishner, M., Detection of relapse in non-Hodgkin's lymphoma: Role of routine follow-up studies (2002) Am J Hematol, 69, pp. 41-44
Jacene, H.A., Filice, R., Kasecamp, W., Wahl, R.L., 18F FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy (2009) J Nucl Med, 50, pp. 8-17
Naumann, R., Vaic, A., Beuthien-Baumann, B., Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma (2001) Br J Haematol, 115, pp. 793-800
Weihrauch, M.R., Re, D., Scheidhauer, K., Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease (2001) Blood, 98, pp. 2930-2934
MacManus, M.P., Seymour, J.F., Hicks, R.J., Overview of early response assessment in lymphoma with FDG-PET (2007) Cancer Imaging, 7, pp. 10-18
Witzig, T.E., Gordon, L.I., Cabanillas, F., Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma (2002) J Clin Oncol, 20, pp. 2453-2463
Morschhauser, F., Illidge, T., Huglo, D., Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation (2007) Blood, 110, pp. 54-58
Gopal, A.K., Rajendran, J.G., Petersdorf, S.H., High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma (2002) Blood, 99, pp. 3158-3162
Zinzani PL, d'Amore F, Bombardieri E, et al. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer 2008
44:366-373Juweid, M.E., Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma (2006) Hematology Am Soc Hematol Educ Program, 259-265, pp. 510-511
Juweid, M.E., Wiseman, G.A., Vose, J.M., Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography (2005) J Clin Oncol, 23, pp. 4652-4661
Assessment of Metabolic Response to Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Purpose: To prospectively compare the assessment of metabolic response to yttrium 90 ((90)Y)-ibritumomab tiuxetan radioimmunotherapy (RIT) by using fluorine 18 ((18)F)fluorodeoxyglucose (FDG) combined positron emission tomographic-computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non-Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twenty-three consecutive patients (10 women, 13 men; mean age, 51.8 years +/- 7.3 [standard deviation]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, (18)F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete (n = 12) or partial (n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These findings were all confirmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49% or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49% (P < .05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identification of patients needing additional therapeutic strategies. (C) RSNA, 2010
Assessment of Metabolic Response to Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
No results.
Assessment of Metabolic Response to Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma